Radnostix Inc (INIS) stock
Close on Oct 19, 2026Market cap $24.87MP/E –Yield –
Radnostix Inc saw revenue fall 23.7% to $11.23M over the twelve months to Jun 30, 2026. Operating income fell 1244.8% to -$2.90M, moving the operating margin from 1.7% to -25.8%. Free cash flow was -$925.24K. At the latest close the market valued the company at $24.87M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $24.87M
- P/E ratio
- –
- Price to sales
- 2.22
- Price to book
- 13.14
- Dividend yield
- –
- Free cash flow yield
- -3.72%
Fundamentals
- Revenue
- $11.23M
- Net income
- -$2.86M
- EPS, diluted
- $0.00
- Free cash flow
- -$925.24K
- Book value per share
- $0.00
- Diluted shares
- 529M
Trading
- Previous close
- $0.05
- Open
- $0.04
- Day's range
- $0.04 – $0.05
- Volume
- 264,300
- Average volume (20 days)
- 77,822
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | INIS | S&P 500 | Difference | INIS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -21.8% | +0.6% | −22.4 pts | ||
| 3 months | -33.1% | +3.4% | −36.5 pts | ||
| Year to date | -23.3% | +13.3% | −36.5 pts | ||
| 1 year | -14.5% | +16.6% | −31.2 pts | ||
| 3 years | -6.0% | +86.4% | −92.4 pts | -2.0% | +23.1% |
| 5 years | -53.0% | +81.9% | −134.9 pts | -14.0% | +12.7% |
| 10 years | -41.3% | +318.9% | −360.1 pts | -5.2% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Radnostix filed with the SEC as exhibits to Form 8-K or 6-K
About Radnostix
Industrial Instruments For Measurement, Display, and Control
Radnostix Inc. manufactures radioisotope-based products for medical, industrial, and research uses. The company operates through five reportable business segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. Its offerings include generic radiopharmaceuticals such as sodium iodide I-131, active pharmaceutical ingredients, radiochemicals, cobalt-60 sealed sources, imaging calibration standards, and lung ventilation medical devices. Radnostix serves radiopharmacies, clinical research organizations, contract development and manufacturing organizations, original equipment manufacturers, environmental laboratories, utilities, and the United States Department of Energy.
Company profile, executives and historyRadnostix stock: common questions
What is Radnostix's stock price?
INIS closed at $0.05 on Oct 19, 2026, down 6.00% on the day.
What is Radnostix's market cap?
Radnostix was worth $24.87M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is INIS's P/E ratio?
Radnostix lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Radnostix make?
Radnostix reported revenue of $11.23M for the twelve months to Jun 30, 2026, down 23.7% from a year earlier.
Does Radnostix pay a dividend?
No. Radnostix has not paid a cash dividend over the last twelve months.
How has INIS stock performed over the past year?
Including dividends, INIS returned -14.5% over the past year, against +16.6% for the S&P 500.
Who are Radnostix's competitors?
Companies most similar to Radnostix by business, industry and size include CLIR, SCND, LCTC, DAIO, SENS.
See a number that looks wrong?